From March 1981 to January 1984, 116 patienst with advanced non-small-cell carcinoma of the lung (NSCCL) were randomly assigned to 3 combinations as follows: CDDP + DVA, CDDP + VP16 and DXR + CTX. 94 patients were evaluable for response, 106 for toxicity and survival. Of 31 patients, 15 (48%; 3 CRs and 12 PRs) responded to CDDP + DVA; of 33 patients, 12 (36%, 2 CRs and 10 PRs) responded to CDDP + VP16; of 30 patients, 3 (10%) obtained a PR with DXR+CTX (CDDP+DVA vs DXR + CTX, P < 0.005; CDDP + VP16 vs DXR + CTX, P < 0.05; CDDP + DVA vs CDDP + VP16, P = NS). The median duration of response was 22 weeks in the CDDP-DVA group, 17 weeks in the CDDP-VP16 group, and 16 weeks in the DXR+CTX group. No significant difference in survival was observed among the 3 groups (median: 43, 47, 41 weeks, respectively). Hematologic and neurologic toxicities were significantly higher in the DVA-containing regimen. Despite the lack of improvement of overall survival with the CDDP-containing combinations over the DXR + CTX control group, the good response rate makes them suitable to be used in combined therapeutic strategies.
Get full access to this article
View all access options for this article.
References
1.
AisnerJ., HansenH.H.: Commentary: current status of chemotherapy for non-small cell lung cancer.Cancer Treat. Rep., 65: 979–986, 1981.
2.
ArmitageP.: Statistical Methods in Medical Research, pp. 363–365. Wiley, New York, 1971.
3.
BrittelJ.C., EaganR.T., IngleJ.N.: Cis-diammine-dichloroplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-diamminedichloroplatinum(II), adriamycin and cyclophosphamide in combination for adenocarcinoma of the lung.Cancer Trtat. Rep., 62: 1207–1210, 1978.
CasperE.S., GrallaR.J., KelsenD.P.: Phase II study of high-dose cis-diamminedichloroplatinum-(II) in the treatment of non-small cell lung cancer.Cancer Treat. Rep., 63: 2107–2109, 1979.
6.
CavalliF.: Cisplatin and VP16 combnation chemotherapy for non-small cell lung cancer. In: HansenH., II World Conference of Lung Cancer, p. 223, Copenhagen, 1980.
7.
De JagerR., LongevalL., KlasterskyJ.: High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party, Belgium.Cancer Treat. Rep., 64: 1341–1364, 1980.
8.
DhingraH.M., ValdiviesoM., BooseD.J.: Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.Cancer Traet. Rep., 68: 671–673, 1984.
9.
DhingraH.M., ValdiviesoM., CarrD.T., ChiutenD.F., FarhaP., MurphyW.K., SpitzerG., Umsa-wasdiT.: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.J. Clin. Oncol., 2: 176–183, 1985.
10.
FerrazziE., ZagonelV., VinanteO.: Vindesine in the treatment of squamous cell carcinoma (WHO I), adenocarcinoma (WHO III) and large cell carcinoma (WHO IV) of the lung.Tumori, 68: 531–536, 1982.
11.
FuksJ.Z., AisnerJ., Van EchoD.A.: Randomized study of cyclophosphamide, doxorubicin and etoposide with or without cisplatin in non-small cell lung cancer.J. Clin. Oncol., 51: 295–301, 1983.
12.
FuksJ.Z., EgorinM.J., AisnerJ.: Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.Cancer Chemother. Pharmacol., 10: 104–108, 1983.
13.
FurnasB.E., WilliamsS.D., EinhornL.H.: Vindesine: an effective agent in the treatment of non-small cell lung cancer.Cancer Treat. Rep., 66: 1709–1711, 1982.
14.
GrallaR.J.: Vindesine and cisplatin combination chemotherapy in non-small cell lung cancer. In: HansenH., II World Conference of Lung Cancer, p. 229, Copenhagen, 1980.
15.
GrallaR.J., CasperE.S., KelsenD.P.: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules.Ann. Intern. Med., 96: 414–420, 1981.
16.
HolstiL.R., MattsonK., GrohnP.: Combined treatment of inoperable bronchial carcinoma by chemotherapy and radiotherapy (Abst.). p. 1820, Proceedings of the 13th International Cancer Congress, Seattle, 1982.
ItriL.M., GrallaR.J., KelsenD.P.: Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer.Cancer, 51: 1050–1055, 1983.
19.
JossR., AlbertoP., BerahtoldW.: Adriamycin/ mitomycin and cisplatinum/VP16-213 combination chemotherapy for non-small cell lung cancer.Proc. ASCO, 1: 142, 1982.
20.
KaplanE.L., MeierP.: Non parametric estimation for incomplete observations.J. Am. Statist. Assoc., 53: 457–481, 1958.
21.
KelsenD.P., GrallaR.J., StooplerM.: Cisplatin, doxorubicin, cyclophosphamide and vindesine combination chemotherapy for non-small cell lung cancer.Cancer Treat. Rep., 66: 247–251, 1982.
22.
KlasterskyJ., NicaiseC., LongevalE.: Cisplatin and etoposide with or without vindesine in non-small cell lung cancer (Abst.), p. 191. The III World Conference on Lung Cancer, Tokyo, 1982.
23.
KlasterskyJ., SculierJ.P., NicaiseC.: Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC Lung Cancer Working Party.Cancer Treat. Rep., 67: 727–730, 1983.
LuedkeD.W., LuedkeS.L., PetruskaP.: A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer.Cancer, 51: 778–782, 1983.
26.
MattsonK., HolstiL.R., SalmaM.: Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results.Cancer Treat. Rev., 7(suppl.): 65–70, 1980.
OsterlindK., HorbouS., DombernowskyP.: Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma and large cell carcinoma of the lung.Cancer Treat. Rep., 66: 305–309, 1982.
29.
PetoR., PikeM.C., ArmitageP.: Design and anaylsis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples.Br. J. Cancer, 35: 1–39, 1977.
30.
RobertF., OmuraG.A., BirchR.: Randomized phase II comparison of three doxorubicin-based regimens in advanced non-small cell lung cancer. A Southeastern Cancer Study Group trial.J. Clin. Oncol., 2: 391–395, 1984.
31.
RossofA.H., BeardenJ.D. I.I.I., ColtmanC.A.Jr.: Phase II evaluation of cis-diamminedichloroplati-num(II) in lung cancer.Cancer Treat. Rep., 60: 1679–1680, 1978.
ScoulierJ.P., KlasteaskyJ.: Progress in chemotherapy of non-small cell lung cancer.Eur. J. Cancer Clin. Oncol., 20: 1329–1333, 1984.
34.
VoglS.E., BerenzweigM., CamachoF.: Efficacy study of intensive cisplatin therapy in advanced non-small cell bronchogenic carcinoma.Cancer, 50: 24–26, 1982.
35.
VoglS.E., ZarovinosT., KaplanB.H.: Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration.Cancer, 45: 11–15, 1980.
36.
WHO handbook for reporting results of cancer treatment (offset publication No. 48), Geneva, 1979, Switzerland, WHO.
